confid pipelin provid
pain relief investor tough tape
probabl toughest tape
seen flash green red tape attest
qualiti print highlight total
beat org rev opex leverag come
better expect one critic
spotti natur perform given confus fx
impact margins/on item revenue impact
straight organ oper beat provid
confid consist execut revenu
front mitg rtg diabet came better
notabl standout mid growth pain
therapi us mid diabet come
better pipelin commentari perhap
bullish comment robot tyrx
heard particular statement
tyrx could caus guidelin chang potenti
implic share gain optim
reflect org revenue guid rais reiter ep
rang despit increment bp hw fx/tariff
support execut thesi think investor
make base case mid-sd organ omx
b/ deploy give visibl high-sd ep growth
dd tsr along div think outlook
choppi market provid safeti downsid offer
upsid multipl catch group average
given outlook reiter outperform rate
ew note tavr grew in-lin market
impli share loss ew could moder
tyrx caus guidelin chang could
put pressur peer push vbc contract
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
compar constant currenc sale growth
prior
impli revenu
fx hold expect ive impact
rev
ep maintain c/c
absorb hw increas fx impact
maintain
cvg slight declin prior chang
acct parti prod go integr
due tougher comp comfort w/ higher-end
fx hw rate hold
slight benefit fx
new launch fy
rtg launch mazor stealth integr robot
navig platform acceler spine
brain therapi react cathetar next gen solitari
graft system expect captur share drive
increment growth especi us
pacemak japan
roll-out recent launch crt-p quad ajur line
mitg expans key specialti area tri-stapl
technolog sonicis ultrason dissect platform
launch next gen consum capnostream
portabl respiratori monitor introduc
diabet global launch within multipl market
well releas next gen sugar iq algo
clinic trial result fy
interim result lori establish studi
result rapid trial tyrx antibacteri envelop
could enabl guidelin chang cardiac rhythm
gen corevalv platform tavr
micra av tran cathet cardiac pacemak target
late fy approv disrupt elig
next-gen cranial mount closed-loop db system
advanc hybrid-clos loop system diabet
advanc cgm center expect steadi cadenc
innov
releas impt event
clinic result publish shortli time come
hasnt chang happen come fruition
robot comfirm track
still digest tct trial result differ result
still lean toward use replac vs repair
go updat timelin b/c still phase
made progress across hardwar softwar verif
launch ou
discuss w/ author around world
intelli sustain innov se
market strong low growth
growth base volume price
clinic vectri nan interim data
surgeon wait data
upsid intelli workflow base
look new indic
take anyth tabl continu
growth last
reiter fy mid low teen impli decal
go back last yr cgm constraint limit
full capac lot pent demand
animi anniversari consum tough
cgm timelin sensor w/ icgm stnd smaller
chang sensor plan
came last yr make tough comp
comp
spine flat mazor improv growth market condit
best core spine biolog infus
vs last yr due cust buy pattern concern b/c
underli strong
market stabil slower yr ago price declin
start inch back littl bit
driver take share
everi major account key robot sale sale
competit integr stealth
placement acct chose pay
w/ increment spine sale last yr
util last yr
implant went
ou strong presenc china spine big driver
speed scale clsoign portfolio gap
look lsd next coupl year
fx hw tariff mazor acquisit impact next year
fx net hw ep
tariff mazor anoth origin guid
comment impact next year use long rang
guid next year given investor day
focu improv cash
growth sustain earn growth
partial due better expect fx
expans improv adjust
currenc driven enterpris excel program
nomin tax rate better expect due
increas deduct exercis employe stock
option along final tax owe certain
csh driven strong growth tavr
de coronari balloon guid cathet
crhf driven msd growth
apv driven high-teen growth
endoven ldd growth dcb msd
growth aaa
si driven advanc energi
driven hsd strength patient
bt driven strength neurovascular
pt driven spinal cord stimul
spine lsd intern flat us
st driven mid-teen growth pelvic
aim growth driven demand
et driven ww strength guardian
train activ user system
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin novemb
analyst william tong alina levchuk vijay kumar primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
